{
    "clinical_study": {
        "@rank": "151365", 
        "acronym": "SPACE", 
        "arm_group": [
            {
                "arm_group_label": "Stereotactic radiotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Arm A: Stereotactic radiotherapy to a dose of 66 Gy at the isocenter with 22 Gy per fraction in 3 fractions during one week with body frame fixation and a planning target volume with a 5 mm margin around the macroscopic tumour. A heterogeneous dose distribution is used so 45 Gy will cover the PTV."
            }, 
            {
                "arm_group_label": "Conventionally fractionated radiotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Arm B: Conventionally fractionated radiotherapy to a dose of 70 Gy with 2 Gy per fraction in 35 fractions during 7 weeks with fixation in a vacuum pillow and a planning target volume with a 2 cm margin around the macroscopic tumour."
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized phase II study for medically inoperable stage I non-small cell lung cancer\n      where stereotactic body radiotherapy in three fractions to 66 Gy is compared with\n      conventionally fractionated radiotherapy to 70 Gy in 35 fractions."
        }, 
        "brief_title": "Stereotactic Precision And Conventional Radiotherapy Evaluation", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multicenter Scandinavian randomized phase II study of stereotactic\n      hypofractionated radiotherapy with body frame versus conventionally fractionated\n      radiotherapy for stage I medically inoperable non-small cell lung cancer patients. There is\n      a 1:1 randomization between arm A: Stereotactic radiotherapy to a dose of 66 Gy with 22 Gy\n      per fraction at the isocenter (45 Gy covers the PTV) in 3 fractions during one week with\n      body frame fixation and a planning target volume with a 5 mm margin around the macroscopic\n      tumour, and arm B: Conventionally fractionated radiotherapy to a dose of 70 Gy with 2 Gy per\n      fraction in 35 fractions during 7 weeks with fixation in a vacuum pillow and a planning\n      target volume with a 2 cm margin around the macroscopic tumour."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Non-small cell lung cancer stage I: T1-2 N0 M0.\n\n          -  Medically inoperable patients or patients refusing surgery.\n\n          -  Morphologically verified. If that is impossible there must be increased  tumour size\n             in repeated CT scans and positive PET.\n\n          -  Patients should have a life expectancy of > 6 months.\n\n          -  WHO performance status 0-2.\n\n          -  Signed written informed consent obtained.\n\n          -  Patient should be feasible for both study arms.\n\n        Exclusion Criteria:\n\n          -  Patients with central tumour growth adjacent to trachea, main bronchus or esophagus.\n\n          -  Maximal tumour diameter > 6 cm.\n\n          -  Patients with prior malignancy within the last five years (except basal cell\n             carcinoma of the skin or in situ carcinoma of the cervix).\n\n          -  Any prior antitumoral treatment of the present lung cancer.\n\n          -  Previous irradiation that included part of the lung.\n\n          -  Pregnant women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "102", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01920789", 
            "org_study_id": "SPACE"
        }, 
        "intervention": [
            {
                "arm_group_label": "Stereotactic radiotherapy", 
                "description": "Margin between CTV and PTV of 5 mm in transversal direction (except for small targets (<3cm) not fixed to thoracic wall or mediastinal structures, where margin should be 10 mm) and 10 mm in longitudinal direction. Planned heterogeneous dose distribution within the PTV with about 50% higher dose to the center compared to the periphery. Hypofractionation with 22 Gy times 3 at the isocenter (15 Gy at the periphery of the PTV)during one week will be used.", 
                "intervention_name": "Stereotactic radiotherapy", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Conventionally fractionated radiotherapy", 
                "description": "Clinical target volume (CTV) comprises the Gross Tumor Volume (GTV), including its diffuse growth at the borders. Planning target volume (PTV) is defined as the CTV with a total margin of 2 cm in all directions. The patient will receive 35 fractions, with a dose of 2.0 Gy/fraction at the ICRU reference point to a total dose of 70 Gy. The treatments will be given five days a week. The total treatment time should be as close to seven weeks as possible. The aim is that the dose distribution should be as homogeneous as possible.", 
                "intervention_name": "Conventionally fractionated radiotherapy", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Non-small call lung cancer", 
            "Medically inoperable", 
            "Stage one", 
            "Radiotherapy", 
            "SBRT", 
            "Hypofractionation", 
            "Conventional fractionation"
        ], 
        "lastchanged_date": "August 8, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Multicenter Randomized Phase II Study of Stereotactic Hypofractionated Radiotherapy With Body Frame Versus Conventionally Fractionated Radiotherapy for Stage I Medically Inoperable Non-small Cell Lung Cancer", 
        "other_outcome": [
            {
                "description": "CTC version 3.0 will be used for acute and late toxicity", 
                "measure": "Toxicity", 
                "safety_issue": "No", 
                "time_frame": "At 7 weeks, 3, 6, 12, 18, 24 and 36 months after randomization"
            }, 
            {
                "description": "EORTC QLQ 30 + LC 14 questionnaire will be used", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "At 7 weeks, 6 and 24 months after randomization"
            }
        ], 
        "overall_official": {
            "affiliation": "Department of Oncology, Sahlgrenska University Hospital", 
            "last_name": "Jan Nyman, Ass. Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "complete remission,partial remission or stable disease", 
            "measure": "Freedom from tumor progression", 
            "safety_issue": "No", 
            "time_frame": "At 36 months after randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01920789"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Swedish Lung Cancer Study Group", 
            "investigator_full_name": "Ass. Prof. Jan Nyman", 
            "investigator_title": "Ass. Prof. Jan Nyman", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "At 36 monts after randomization"
        }, 
        "source": "Swedish Lung Cancer Study Group", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "G\u00f6teborg University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Karolinska Institutet", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Ass. Prof. Jan Nyman", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}